Healthcare Private Placement and M&A Transactions Review Week Ending November 27 2022

LENZ Therapeutics: The company raised $49 million of Series A venture funding from Versant Ventures, RA Capital Management and other undisclosed investors on November 22, 2022, putting the company’s pre-money valuation at $70 million. The company is a developer of ophthalmic pharmaceutical products designed to aid in the treatment of presbyopia.

Temedica: The company raised EUR 42 million of Series B venture funding in a deal led by MIG AG on November 23, 2022. The company is a developer of a real-world evidence platform designed to improve patient care.

Opna Bio: The company raised $38 million of Series A venture funding in a deal led by Longitude Capital and Northpond Ventures on November 21, 2022. The company is a developer of an oncology therapeutics business designed for targeting the markers of cancer.

Care.ai: The company raised $27 million of venture funding led by Crescent Cove Advisors on November 21, 2022. The company is a developer of a sensor-based technology designed to detect and evaluate a range of patient behaviors.

Curevo Vaccine: The company raised $22 million of Series A1 venture funding from GC Biopharma, RA Capital Management and Adjuvant Capital on November 21, 2022. Janus Henderson Investors also participated in the round. The company is an operator of a biotechnology firm dedicated to reducing the effects of infectious illnesses and addressing unmet medical needs globally.

Nyra Medical: The company raised $20 million of Series A venture funding in a deal co-led by Vensana Capital on November 23, 2022. Broadview Ventures, Epidarex Capital and GRA Venture Fund also participated in the round. The company is a developer of a structural heart technology device designed for heart valve leaflets.

Accession Therapeutics: The company raised GBP 16.6 million of venture funding from Primavera Capital Group, Birk Venture and iGlobe Partners on November 21, 2022. The company is a developer of a novel immuno-oncology therapeutics platform designed to treat intractable and widespread forms of cancer.

Alpheus Medical: The company raised $14 million of Series A venture funding from undisclosed investors on November 25, 2022. The company is an operator of a biotechnology business intended to offer sonodynamic therapy for the treatment of brain tumors using ultrasound.

Qunomedical: The company raised EUR 10 million of venture funding from MS&AD Ventures, Bertelsmann Investments and Calm/Storm Ventures on November 22, 2022. Dieter von Holtzbrinck Ventures and US Fund also participated in the round. The company is a developer of a digital medical platform intended to connect patients with doctors.

Wesper: The company raised $9.6 million through a combination of Series A, Series A1, and Series A2 venture funding from Ceros Financial Services, Valor Equity Partners and Breyer Capital on November 21, 2022, putting the company’s pre-money valuation at $40 million. Krillion Ventures and Spark Capital also participated in the round. The company is a developer of a topical patch for sleep medicine.

NanoHive Medical: The company announced it will raise $3.5 million of venture funding on an undisclosed date. The company is a developer of 3D-printed spinal interbody implants and instruments designed to address spinal fusion challenges with bioactive titanium devices.

NewAmsterdam Pharma / Frazier Lifesciences Acquisition: The company was acquired by Frazier Lifesciences Acquisition Corporation through a reverse merger for an estimated $328 million, resulting in the combined entity trading on the Nasdaq Capital Market under the ticker symbols “NAMS”, on November 23, 2022. NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer’s disease.

Contract Laboratory / LabX Media Group: The company was acquired by LabX Media Group for an undisclosed amount on November 22, 2022. The company is an operator of a web-based platform for laboratory outsourcing.

Empire Genomics / Biocare Medical: The company was acquired by Biocare Medical, via its financial sponsors BroadOak Capital Partners, Excellere Partners and GHO Capital, through an LBO on November 22, 2022 for an undisclosed amount. The company is a developer of a molecular and cytogenetic diagnostic platform designed to offer a comprehensive menu of assay services for use in diagnosing and guiding precise therapeutic treatments for patients.

Graybug Vision / CalciMedica: The company  reached a definitive agreement to be acquired by CalciMedica through a reverse merger, resulting in the combined entity trading on the Nasdaq Global Market Exchange on November 21, 2022. Graybug Vision Inc is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve.

Medicus Laboratory Information Systems / CompuGroup Medical: The company reached a definitive agreement to be acquired by CompuGroup Medical for an undisclosed amount on November 22, 2022. The company is a developer of Information software catering to physician office laboratories.

Methuselah Health / RxCelerate: The company was acquired by RxCelerate for an undisclosed amount on November 22, 2022. The company is a developer of a drug designed for proteome instability in a number of human diseases.

Snapdragon Chemistry / Cambrex: The company entered into a definitive agreement to be acquired by Cambrex, via its financial sponsor Permira, through an LBO on November 21, 2022 for an undisclosed amount. The company is a developer of a sampling relay system and photoreactor intended for the chemical pharmaceuticals industry.